Compounds > cgp 43371
Page last updated: 2024-11-11

cgp 43371

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CGP 43371: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11766462
MeSH IDM0215309

Synonyms (9)

Synonym
cgp 43371
n,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-4-o-methyl-3-(4-((2,4,6-trimethyl)methyl)-1-piperazinyl)rifamycin 8-(2,2-dimethylpropanoate)
cgp-43371
rifamycin, n,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-3-(4-((2,4,6-trimethylphenyl)methyl)-1-piperazinyl)-, 8-(2,2-dimethylpropanoate)
123036-23-7
v97741gkf2 ,
unii-v97741gkf2
n,15-didehydro-15-deoxo-1-deoxy-1,15-epoxy-8-o-pivaloyl-3-(4-(2,4,6-trimethylbenzyl)-1-piperazinyl)rifamycin
[(12z,14e,16s,17s,18r,19r,20r,21s,22r,23s,24e,27s)-21-acetyloxy-6,17,19-trihydroxy-23-methoxy-2,12,16,18,20,22,27-heptamethyl-28-oxo-7-[4-[(2,4,6-trimethylphenyl)methyl]piperazin-1-yl]-10,26,30-trioxa-31-azapentacyclo[25.2.1.18,11.04,9.05,29]hentriaconta-

Research Excerpts

Bioavailability

The relative bioavailability of a capsule formulation and the effects of food on the pharmacokinetics of a hypolipidemic agent (CGP 43371) was examined. The results of fecal analysis indicated that transit of the two compounds in the gastrointestinal tract were similar.

ExcerptReferenceRelevance
"The relative bioavailability of a capsule formulation and the effects of food on the pharmacokinetics of a hypolipidemic agent (CGP 43371) in 12 healthy subjects were examined."( Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects.
Chan, K; Cipriano, A; John, VA; Klibaner, M; Sun, JX, 1994)		0.29
" The results of fecal analysis indicated that transit of the two compounds in the gastrointestinal tract were similar, and bioavailability of CGP 43371 was calculated to be 9% based on the difference between the cumulative amounts of the nonabsorbable radioactive marker and CGP 43371 found in the feces."( Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics.
Chan, K; Cipriano, A; Digenis, GA; Maniara, WM; Page, RC; Powell, ML; Ryo, UY; Sandefer, EP; Sun, JX; Walter, B, 1996)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
samarium
Samarium: An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.		1.9910f-block element atom;
lanthanoid atom
rifamycins
[no description available]		1.9810
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		5.3272cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		0210